Amgen's fourth-quarter 2023 earnings call highlighted several positive and promising aspects of the company's performance and future outlook. Here are the key points:

- **Strong Financial Performance**: Amgen reported a 20% increase in total revenues for the fourth quarter, driven by 23% volume growth, and a 7% increase in full-year revenues. Non-GAAP EPS grew 15% for the quarter and 5% for the full year[1][3].
- **Horizon Therapeutics Acquisition**: The acquisition, completed on October 6, 2023, has added significant rare disease products, including TEPEZZA, KRYSTEXXA, and UPLIZNA, which are contributing to Amgen's growth and diversifying its portfolio[1][4].
- **Pipeline Progress**: Amgen is advancing several promising pipeline assets, including Tarlatamab, MariTide, and TEZSPIRE, with multiple significant pipeline milestones anticipated in 2024. The company is also investing heavily in R&D, with a focus on innovation and patient care[1][3].
- **Guidance for 2024**: Amgen provided a strong guidance for 2024, expecting revenue of $32.4 billion to $33.8 billion and non-GAAP EPS of $18.90 to $20.30. The acquisition of Horizon is expected to be accretive to non-GAAP EPS in 2024[1][3].

Given these points, the overall tone of the call was positive, reflecting strong execution, significant pipeline progress, and a robust financial outlook. This suggests that the stock is likely to benefit from these factors in the short term.

**Rating: 2**